Comparative Immunogenicity of Plasma and Recombinant Hepatitis B Virus Vaccines in Homosexual Men

Nancy Odaka, Lois Eldred, Sylvia Cohn, Alvaro Muñoz, Howard A. Fields, Robin Fox, Rachel Solomon, Richard Kaslow, B. Frank Polk

Research output: Contribution to journalArticle

Abstract

A randomized, double-blind clinical trial of plasma-derived and DNA recombinant hepatitis B virus vaccines was conducted in 186 homosexual men. Nine months after the immunization series (three doses) began, the seroconversion rate in the plasma vaccine group was 88% (68/77); this was significantly higher than the 74% (60/81) response rate of the recombinant vaccine group. Men positive for antibody to the human immunodeficiency virus (HIV) had a considerably higher nonresponse rate to either vaccine than expected in non—HIV-infected homosexual men. The odds ratios of nonresponse to hepatitis B virus vaccine for HIV-seropositive vs HIV-seronegative subjects were 12.0 (95% confidence interval, 1.7to 89.3) and 13.6 (95% confidence interval, 2.3 to 148.3) for the plasma and DNA recombinant vaccines, respectively.

Original languageEnglish (US)
Pages (from-to)3635-3637
Number of pages3
JournalJAMA: The Journal of the American Medical Association
Volume260
Issue number24
DOIs
StatePublished - Dec 23 1988

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Comparative Immunogenicity of Plasma and Recombinant Hepatitis B Virus Vaccines in Homosexual Men'. Together they form a unique fingerprint.

  • Cite this